1e
19
1
49
2
2
18
1b
1d
18
33
68
1d
2 29
1d
25
Ihab Michel Wahba, MD
78
68
Professor of Clinical Medicine (Renal-Electrolyte and Hypertension)
28
73
3
5f
Chief, Section of Nephrology, Philadelphia VA Medical Center
7c
Medical Director, Outpatient Dialysis, Philadelphia VA Medical Center
7b
Medical Director, Inpatient Dialysis, Philadelphia VA Medical Center
7e
Director, Resistant Hypertension Clinic, Philadelphia VA Medical Center
6d
Co-Chair, VISN4 Dialysis Council, CMCVAMC Philadelphia
11
Department: Medicine
4
1
b
1d
46
Contact information
32
4
3
3
3
2
29
32
VAMC
34 3900 Woodland Ave
Philadelphia, PA 19104
26
34 3900 Woodland Ave
Philadelphia, PA 19104
2e
Office: 215-662-7934
30
a3
12
30
Links
86 Philadelphia Corporal Michael J. Crescenz VA Medical Center
de Penn's Renal-Electrolyte and Hypertension Division
c
4
b
1f
86 Philadelphia Corporal Michael J. Crescenz VA Medical Center
de Penn's Renal-Electrolyte and Hypertension Division
c
13
Education:
21 e M.B.B.Ch. c
29 Cairo University, 1991.
c
3
3
3
3
8d
Permanent link21 e M.B.B.Ch. c
29 Cairo University, 1991.
c
2 29
21
1e
1d
24
5e
1e Resistant hypertension
35 Disorders of water balance (Sodium disorders)
1b Acid-base disorders
1c Drug nephrotoxicity
23 Drug dosing in CKD and ESRD
15 Dialysis care
25 Gadolinium and kidney disease
24 Nephrogenic systemic fibrosis
62
65
1b Drug nephrotoxicity
1c Cardiorenal syndrome
24 Intra-abdominal hypertension
21 Obesity and renal disease
1b Acute kidney injury
1d Resistant hypertension
e 29
27
Description of Clinical Expertise
25 Cardiorenal syndrome1e Resistant hypertension
35 Disorders of water balance (Sodium disorders)
1b Acid-base disorders
1c Drug nephrotoxicity
23 Drug dosing in CKD and ESRD
15 Dialysis care
25 Gadolinium and kidney disease
24 Nephrogenic systemic fibrosis
62
Description of Other Expertise
40 Teaching medical students, residents and fellows65
Description of Research Expertise
28 Drug dosing in dialysis1b Drug nephrotoxicity
1c Cardiorenal syndrome
24 Intra-abdominal hypertension
21 Obesity and renal disease
1b Acute kidney injury
1d Resistant hypertension
e 29
23
d3 Pennekamp A, Wahba I: Importance of MAP reduction for AKI induction in type 1 cardiorenal syndrome. Am J Kidney Dis 2023 Notes: In Press.
100 Rudnick MR, Fay K, Wahba IM: Fluid administration strategies for the prevention of contrast-associated acute kidney injury. Curr Opin Nephrol Hypertens 31(5): 414-424, September 2022.
fe Rudnick MR, Wahba IM, Leonberg-Yoo AK, Miskulin D, Litt HI: Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review. Am J Kidney Dis 4: 517-528, 2021.
e2 Rudnick M, Wahba IM, Miskulin D: Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced kidney disease. UpToDate April 2020- Current.
fd Srinivasan V, Ahmad S, Aggarwal S, Wahba I, Huan Y: COVID-19 infection patterns in an academic inner city dialysis unit. Journal of the American Society of Nephrology October 2020.
123 Rudnick M, Wahba IM, Leonberg-Yoo A: Use of Gadolinium-Based Contrast Agents in Patients with Severe Renal Impairment. Absence of Risk Versus Caution: A Nephrologist’s Perspective. Kidney360 1(6): 433-435, June 2020.
120 Fink JC, Joy MS, St Peter WL, Wahba IM; ASN Chronic Kidney Disease Advisory Group.: Finding a common language for patient safety in CKD. Clin J Am Soc Nephrol 7(4): 689-95, Apr 2012 Notes: doi: 10.2215/CJN.12781211.
e7 Dadfarmay S, Wahba IM : Acute kidney injury due to pulmonary embolism: The case for congestive kidney failure. Nephrol Dial Transplant Plus 4: 295-298, 2011.
bc Wahba IM: The renal consequences of obesity- What have we learned in recent years? US Nephrology 3(2): 12-15, 2009.
2c
7
1d
1f
Selected Publications
aa Wahba IM: Gadolinium and kidney disease: Should we still be cautious? Clin J Am Soc Nephrol 2025.d3 Pennekamp A, Wahba I: Importance of MAP reduction for AKI induction in type 1 cardiorenal syndrome. Am J Kidney Dis 2023 Notes: In Press.
100 Rudnick MR, Fay K, Wahba IM: Fluid administration strategies for the prevention of contrast-associated acute kidney injury. Curr Opin Nephrol Hypertens 31(5): 414-424, September 2022.
fe Rudnick MR, Wahba IM, Leonberg-Yoo AK, Miskulin D, Litt HI: Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review. Am J Kidney Dis 4: 517-528, 2021.
e2 Rudnick M, Wahba IM, Miskulin D: Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced kidney disease. UpToDate April 2020- Current.
fd Srinivasan V, Ahmad S, Aggarwal S, Wahba I, Huan Y: COVID-19 infection patterns in an academic inner city dialysis unit. Journal of the American Society of Nephrology October 2020.
123 Rudnick M, Wahba IM, Leonberg-Yoo A: Use of Gadolinium-Based Contrast Agents in Patients with Severe Renal Impairment. Absence of Risk Versus Caution: A Nephrologist’s Perspective. Kidney360 1(6): 433-435, June 2020.
120 Fink JC, Joy MS, St Peter WL, Wahba IM; ASN Chronic Kidney Disease Advisory Group.: Finding a common language for patient safety in CKD. Clin J Am Soc Nephrol 7(4): 689-95, Apr 2012 Notes: doi: 10.2215/CJN.12781211.
e7 Dadfarmay S, Wahba IM : Acute kidney injury due to pulmonary embolism: The case for congestive kidney failure. Nephrol Dial Transplant Plus 4: 295-298, 2011.
bc Wahba IM: The renal consequences of obesity- What have we learned in recent years? US Nephrology 3(2): 12-15, 2009.
2c